Financial Report: Johnson & Johnson 1Q11

Johnson & Johnson 1Q11

1Q Revenues: $16.2 billion (+4%)

1Q Earnings: $3.5 billion (-23%)

Comments: Worldwide Pharmaceutical sales were $6.1 billion in the quarter (+8%), with domestic sales down 1% and international sales up 7%. Remicade sales were up 8% to $1.3 billion. Levaquin/Floxin sales were up 17% to $434 million. Concerta sales were up 10% to $362 million. Prezista sales were up 42% to $266 million. Procrit/Eprex sales were down 24% to $397 million. Topamax sales were down 13% to $129 million. Worldwide Consumer sales were $3.7 billion (-2%), with domestic sales down 14%, impacted by the suspension of manufacturing at the McNeil Consumer Healthcare facility in Fort Washington, PA. International sales increased 6%. Worldwide Medical Devices and Diagnostics sales were $6.4 billion (+3%).